Abstract: Described herein is a composition useful for inducing expression of genes whose expression is under control of an inducible promoter sequence and methods for the compositions preparation and use.

Abstract: A method for preparing an anti-hypertension peptide composition, using a microbe which is intrinsic to common soybean food and capable of producing protease. The composition mainly contain peptides with a molecular weight of less than 10 kD which are produced by decomposition of soy proteins by the microbe in a fermentation process. The composition is shown to have an ACE inhibitory activity and an effect of lowering blood pressure when administered to a mammalian subject.

Abstract: A new nucleic acid molecule that is codon-optimized to expressbeta interferon in Escherichia coli with greater efficacy.

Abstract: The present invention provides compositions and methods for treating or preventing hyperacute rejection.

Abstract: The present invention relates to Bacillus licheniformis B1 strain, alkalophilic enzyme solution and a method for preparing the same, in particular the method for producing cellulase demonstrating optimal activity at pH 10-13 by using Bacillus licheniformis B1 strain. The enzyme produced by the method of the present invention and the enzyme solution containing the same have excellent enzyme activity in alkali condition, so that they can be effectively applied in diverse uses including the production of detergent or bio-fuel.

Abstract: The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B Streptococcus serotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence. Thus, the adhesin island proteins of the invention may be used in immunogenic compositions for prophylactic or therapeutic immunization against GAS or GBS infection. For example, the invention may include an immunogenic composition comprising one or more of the discovered adhesin island proteins.

Abstract: The invention relates to the production of ligninolytic enzymes, laccase and manganese peroxidase, from certain white-rot basidiomycetes fungi, using highly efficient fermentation techniques. The aim of this invention is to create a novel economically and time-effective overall procedure comprising use of specific mushroom strains, fermentation process and the isolation-purification techniques, for producing the aforesaid enzymes. In particular, a submerged fermentation of the specific strains on a variety of lignocellulosic substrates from organic wastes like waste of ethanol production from wheat grain, mandarin peels and bran is developed. Culturing conditions can be selected to modify the laccase/manganese peroxidase ratio in favour of the production of either laccase or manganese peroxidase.

Abstract: The invention relates to a peptide compound with biological activity, which in particular possesses antimicrobial properties, its preparation and its applications.

Abstract: The present invention discloses an improved process for the production of G-CSF in high yield via a high salt-induced increase in plasmid stability during the production phase.

Abstract: The present invention relates to a DNA molecule or vector and a host cell containing this DNA molecule or vector which can be used to produce a heterologous polypeptide under conditions that elicit a cold shock response in the host cell. The DNA molecule and vector include a nucleotide sequence encoding a heterologous polypeptide and a promoter and 5?-UTR from a cold shock inducible gene which directs its expression. In addition, an AT-rich sequence that enhances translation under cold shock inducible conditions is either present in the coding sequence of the heterologous polypeptide or in an additional element inserted between the coding sequence and the cold shock inducible promoter and 5?-UTR.

Abstract: The present invention relates to an active agent, in particular a metalloproteinase inhibitory agent of casein-derived peptides obtained by hydrolysis of casein by a food grade bacteria. The invention also relates to the manufacture of an active agent, in which a food grade bacteria of the genus Lactobacillus helveticus is contacted with casein in order to perform a hydrolysis and obtain casein-derived peptides exhibiting metalloproteinases inhibitory property. The present invention also includes isolated and purified inhibitory peptides obtained by hydrolysis of casein by the bacteria.

Abstract: Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such as a protein, lipoteichoic acid or carbohydrate from the cell-wall material and contacting the proteinaceous substance with the cell-wall material.

Abstract: The present invention relates to the use of bacteriophages to treat infectious diseases. The invention provides a method for intermediate to large scale commercial production of bacteriophage compositions, wherein the method reduces the production volume and elevates production yield. The invention further relates to improved bacteriophage compositions comprising specific sugars that reduce or abolish the bacterial phage-neutralizing activity.

Abstract: The present invention comprises a method for assaying oxygenase activity the method comprising monitoring oxygenase activity of Mina53.

Abstract: The invention provides an improved process for preparing romidepsin. The process involves producing, purifying, or storing romidepsin under conditions that prevent the formation of undesired adducts. Purifying romidepsin at an apparent pH lower than approximately 6.0 (e.g., between an apparent pH of 4.0 and 6.0) has been discovered to prevent the reduction of the disulfide bond of romidepsin and the subsequent formation of dimerized, oligomerized, or polymerized adducts. The invention also provides compositions of monomeric romidepsin free of dimerized, oligomerized, or polymerized adducts.

Abstract: An object is to provide an interleukin production regulator which can be used for prevention, treatment or recurrence prevention of a gastrointestinal disease or an autoimmune disease accompanied by an inflammation as the main symptom, which is highly safe, and which can be administered over a long period. Another object is to provide a method for production of the interleukin production regulator. Further object is to provide a pharmaceutical composition and a food, each of which comprises the interleukin production regulator. Disclosed are: a method for producing an interleukin production regulator having both an effect of maintaining or promoting the production of interleukin-10 and an effect of maintaining or inhibiting the production of interleukin-12, comprising the step of disrupting a cell of a microorganism belonging to the genus Bifidobacterium; an interleukin production regulator produced by the method; and a pharmaceutical and a food, each comprising the interleukin production regulator.

Abstract: The present application relates to cyclic depsipeptides, or derivatives thereof, having the structure of formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7 and human neutrophil elastase.

Abstract: A method for reducing the formation of a byproduct polypeptide containing an O-acetylserine residue in place of a serine residue by adding at least one of histidine, methionine or glycine to the medium in a method for producing a polypeptide containing a serine residue by culturing transformed cells, and a method for producing a polypeptide containing a serine residue by culturing transformed cells, characterized by reducing the formation of a byproduct polypeptide containing an O-acetylserine residue in place of a serine residue by adding at least one of histidine, methionine or glycine to the medium.

Abstract: The present invention relates to novel JP170 like subtilases from wild-type bacteria, hybrids thereof and to methods of construction and production of these proteases. Further, the present invention relates to use of the claimed subtilases in detergents, such as a laundry or an automatic dishwashing detergent.

Abstract: The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.

Abstract: A method for the production of the N-terminal four kringle-containing fragment of hepatocyte growth factor (NK4) by expression of a nucleic acid encoding said NK4 in a microbial host cell, isolation of inclusion bodies containing said NK4 in denatured form, solubilization of the inclusion bodies and naturation of the denatured NK4, characterized in that solubilization and naturation are performed at pH 7-9 in phosphate buffered solution, provides NK4 in high purity and high yield.

Abstract: The invention relates to a method for producing biomass from halophilic organisms, in which the halophilic organisms are fermented in a hollow space in a salt dome and said halophilic organisms or components thereof are isolated as biomass.

Abstract: Conductive nanowires, as are available from a range of bacteria species, methods of use and related device structures.

Abstract: The present invention provides a phospholipase C enzyme(s) having ability to hydrolyze phospholipid in both acidic and around neutral ranges and the activity in a citrate buffer solution as well as having some degree of heat stability, and having a property not to hydrolyze phosphate esters not containing lipid moieties. The phospholipase C enzyme(s) shows the activity at from acidic to neutral pH and does not substantially hydrolyze any phosphate esters except for phospholipids.

Abstract: A method is provided for producing hIGF-I with high purity and yield. This is a method for producing human insulin-like growth factor I, having a step of removing modified human insulin-like growth factor I from the human insulin-like growth factor I, the step including: (A) a step of adjusting the pH of a culture liquid of a human insulin-like growth factor I producing bacteria to 8 or more after completion of culture; (B) a step of letting the culture liquid obtained in step (A) stand; and (C) a step of removing the producing bacteria from the culture liquid obtained in step (B).

Abstract: The present invention provides an expression vector comprising genes encoding OmpF of E. coli and a desired protein, E.coli transformed with the expression vector, and a method for extracellular production of desired proteins by employing the same. The recombinant expression vector of the invention comprises an ampicillin-resistance gene, the OmpF promoter and the OmpF gene. In accordance with the invention, a desired protein can be produced extracellularly by a simpler method than conventional methods such that: secretory production of OmpF fusion protein begins simultaneously with growth of the cells through constitutive expression employing an OmpF promoter, and as the concentration of cells increases, the amount of secretory production of the protein also increases continuously. Therefore, desired proteins can be produced in large quantities by a high concentration culture of cells.

Abstract: Improved expression of active antibody fragments (Fabs) is achieved by truncating a heavy chain constant region. Truncation of the CH1 domain of a Fab fragment can increase yield of soluble active antibody fragment in Pseudomonas fluorescens. Another embodiment of the invention includes secretion of the light chain and a fragment of the heavy chain with various C-termini (e.g., VH-CH1 truncated to different lengths). The truncated CH1 region can be used as a scaffold to create other Fabs. Also included is truncation of the kappa light chain and/or lambda light chain domains of a Fab fragment. The invention also includes expression of Fab fragments fused to other peptides or molecules (e.g., toxins, proteins, peptides, enzymes, etc.).

Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, using vesicle vaccines made from Neisseria strains have decreased or no detectable expression of a product of LpxL1 gene, and which optionally overexpress fHbp.

Abstract: The present invention relates to fermentation processes for the production of cyanophycin in a microorganism whereby a plant-derived nitrogen source is converted by the microorganism into cyanophycin. The plant-derived nitrogen source preferably is a process stream being obtained in the processing of agricultural crops such as e.g., a by-product in the processing of starch from agricultural crops like corn, potato or cassave. The invention further relates to processes for the conversion of cyanophycin into a variety of compounds including e.g., ornithine, 1,4-butanediamine, n-alkyl amino alcohols, acrylonitrile, as well as cyanophycin derived functionalised poly(aspartic acid)s wherein the arginine residues have been functionalised to ornithine, (N-L-arginino)succinate, N-phospho-L-arginine or agmantine and the lysine residues have been functionalised to N6-hydroxy-L-lysine, 2,5-diaminohexanoate, N6-(L-1,3-dicarboxypropyl), pentanediamine, 5-aminopentanamide or N6-acetyl-L-lysine.

Abstract: Alanine 2,3-aminomutase sequences are disclosed, as are cells having alanine 2,3-aminomutase activity and methods of selecting for such cells. Methods for producing beta-alanine, pantothenate, 3-hydroxypropionic acid, as well as other organic compounds, are disclosed.

Abstract: The invention relates to an immunogenic composition, characterized in that it comprises an adenyl cyclase-hemolysin (AC-Hly) protein, or an immunogenic portion of this AC-Hly, of a strain of Bordetella chosen from B. pertussis, B. parapertussis or B. bronchiseptica, and in that it comprises, in addition, a bacterial extract containing the expression products of the vrg genes of a strain of Bordetella chosen from B. pertussis, B. parapertussis or B. bronchiseptica, or a portion of these expression products which is sufficient to induce an immune response in a host to which the extract might be administered.

Abstract: The disclosure below provides a protein export system for efficiently producing recombinant protein from a host cell. In a preferred embodiment, the protein export system utilizes protein export machinery endogenous to the host bacterium into which the protein export system vector is introduced.

Abstract: Modified neurotoxins that contain protease cleavage sites susceptible uniquely to proteases present in certain tissues are described. The toxins can be selectively activated by proteases in muscle or selectively inactivated by proteases in blood.

Abstract: The invention relates to the field of bacteriocin producing microorganisms. The invention more specifically relates to the characterization of a novel food grade bacteriocin, namely a lantibiotic, named macedocin and produced by Streptococcus macedonicus ACA-DC 198. Macedocin inhibit a broad spectrum of lactic acid bacteria as well as several food spoilage and pathogenic bacteria, among others Clostridium tyrobutyricum, and is heat stable and active in a broad pH range. The invention further relates to the use of non-pathogenic microorganisms for producing macedocin in food fermentation processes, such as for preparing milk products, butter, cheese and fermented meat and vegetables, as well as in non-fermented food products such as raw meat, modified atmosphere-packed meat products, ready-to-eat meals, and canned food products, and its use for the preparation of functional starter cultures and cocultures.

Abstract: It is intended to provide a thermostable AMP deaminase originating in a microorganism. Namely, an AMP deaminase having the following characteristics. (1) Catalyzing the reaction: 5?-adenylic acid+H2O?5?-inosinic acid+NH3; (2) being stable at a temperature of 65° C. or below (in an acetate buffer (pH 5.6)); (3) having a molecular weight of 48,000±2,000 in gel filtration; and (4) having the optimum pH value at around 5.6 (in McIlvaine buffer).

Abstract: The present invention relates to a method for obtaining highly purified hydrophobic proteins from cells by extraction using a buffer containing a detergent and removal of said detergent by hydroxyapatite (HA) column chromatography.

Abstract: The invention provides novel biologically pure cultures of microorganisms high in protease activity and capable of decomposing proteins recalcitrant to proteolysis as contained in garbage, waste water, organic waste liquids, industrial wastes and the like, a protease produced by such microorganisms and capable of decomposing proteins recalcitrant to proteolysis, and a method of utilizing the same. The novel culture is of a soil-derived microorganism belonging to Streptomyces sp., or a strain derived therefrom, which produces a protease capable of efficiently decomposing proteins recalcitrant to proteolysis as contained in waste water, organic waste liquids, industrial wastes and so forth.

Abstract: The present invention provides a completely novel molting hormone receptor, which is used for efficiently screening a substance that can be applied to a disinfestant or the like. An insect molting hormone receptor comprising the following polypeptide (a) and polypeptide (b) or (c): (a) a polypeptide having the amino acid sequence shown in SEQ ID NO: 1; (b) a polypeptide having the amino acid sequence shown in SEQ ID NO: 2; and (c) a polypeptide having the amino acid sequence shown in SEQ ID NO: 3.

Abstract: Proteins capable of modulating or mediating the function of MORT-1 are disclosed. Also disclosed are DNA sequences encoding these proteins, the recombinant production of these proteins as well as their use.

Abstract: The present invention relates to method for selective reduction and derivatization of recombinantly prepared engineered proteins comprising at least one non-native cysteine, wherein the reduction reaction is conducted in the presence of a redox buffer or in the presence of a triarylphosphine reducing agent.

Abstract: The present invention relates to a process of producing desired enzyme(s) in a host cell, comprising cultivating said host cell capable of producing the desired enzyme(s) under conditions conducive for production of the desired enzyme(s) using a substrate for the host cell comprising liquefied and/or saccharified starch-containing plant material.

Abstract: Provided is a high-copy-number, high-expression vector capable of producing a protein having satisfactory functions and activity of the same level as that of a natural form of the protein, in a large quantity and in a simple manner. Also provided is a vector including: (A) a target gene or a cloning site of the target gene, (B) a sequence element necessary for the high copying of the target gene, (C) a sequence element necessary for the expression of the target gene and a methionine aminopeptidase gene; a method of producing the vector; a transformant having the vector introduced therein; and a process for producing a protein using the transformant.

Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant.

Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.

Abstract: The invention provides bacteriophages that infect Bacillus bacteria, including Bacillus anthracis, and compositions containing the bacteriophages. The invention also provides methods for using the bacteriophages of the invention to prevent and treat infection of an organism by Bacillus bacteria. Methods and materials to decontaminate a surface or an organism that is contaminated with Bacillus bacteria or Bacillus spores is also provided.

Abstract: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group (FIG. 1).

Abstract: A method for identifying virulent strains of L. monocytogenes that includes the use of primers or probes in a PCR assay or hybridization technique that employs primers or probes, which are specific for virulence-specific genes of L. monocytogenes. Also provided is a method of control of L. monocytogenes strains that have been identified using the method of the present invention.

Abstract: The present invention relates to a process for producing a heterologous protein by means of an E. coli strain in a fermentation medium, in which an E. coli strain which has a mutation in the lpp gene or in the promoter region of the lpp gene, and contains a gene coding for a heterologous protein which is functionally linked to a signal sequence coding for a signal peptide, is fermented on an industrial scale in the fermentation medium, with the E. coli strain secreting the heterologous protein into the fermentation medium, and the protein being removed from the fermentation medium, wherein the heterologous protein comprises more than 70 amino acids.

Abstract: Biological macromolecules are synthesized in vitro in a thin film that provides for high surface area/volume ratio, allowing improved yield in scaled up reactions.

Abstract: Biological macromolecules are synthesized in vitro under conditions and in a reaction composition wherein oxidative phosphorylation is activated and protein folding is improved.